New Data on Sovaldi Bolsters Gilead’s Bid to Dominate the Hep C Market

Drug Industry Daily
A A
Gilead Sciences’ drug Sovaldi appears primed to dominate the hepatitis C market with the release of new Phase III trial data showing subjects with genotype 1 of the virus benefit from the drug, without coupling it with interferon.

To View This Article:

Login

Subscribe To Drug Industry Daily